Search Results - non-novel

60 Results

Sort By:

Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice

INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...

Published: 5/9/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Farnesylation of PARIS Prevents Dopaminergic Neurodegeneration in Models of Parkinson’s Disease

Unmet Need: Parkinson's disease (PD) is an incurable progressive neurodegenerative disease. It is characterized clinically by motor dysfunction that is due to the preferential loss of dopaminergic neurons in the brain. Current treatment strategies for PD are mainly limited to the management of the motor symptoms with drugs such as L-DOPA or dopamine...

Published: 5/9/2024 | Inventor(s): Ted Dawson, Valina Dawson, Joo-Ho Shin, Yunjong Lee, Areum Jo

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Non-novel, Off-the-shelf, Parkinson's Disease, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Parkinson's Disease

Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis

Unmet NeedAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life expectancy from diagnosis to mortality is between 2-5 years....

Published: 5/9/2024 | Inventor(s): Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Pharmacological Intervention of the Arachidonic Acid Pathway to Cure Amyotrophic Lateral Sclerosis

Unmet NeedAmyotrophic Lateral Sclerosis (ALS) affects as many as 30,000 people in the United States alone, with 5,000 new cases diagnosed every year. ALS is a fatal neuromuscular disease that is characterized by a progressive degeneration of the motor nerve cells and spinal cord. There are only two drugs approved by FDA for the treatment of ALS, and...

Published: 5/9/2024 | Inventor(s): Gabsang Lee, Hyungjin Eoh, Hojae Lee, Thomas Lloyd, Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, CNS and Neurological Disorders, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Identification of Novel Coumestan Derivatives as Pks13 Inhibitors against Mycobacterium Tuberculosis

Unmet NeedTuberculosis (TB) is an infectious disease caused by the bacteria Mycobacterium tuberculosis (Mtb), which typically impacts the lungs. In 2016, there were 10.4 million new cases of TB and 1.7 million deaths worldwide, with approximately one-fourth of the world’s population infected. As a result, TB is one of the leading infectious disease...

Published: 5/9/2024 | Inventor(s): William Bishai, Shichun Lun, Li-Fang Yu, Shu-Huan Wang, Fan Yang, Jie Tang, Hendra Gunosewoyo, Ashlee Earl, Abigail Manson, Wei Zhang

Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Myobacterium Tuberculosis, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Tuberculosis (TB)

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB)

Low Dose Adjuvant Epigenetic Modifiers Inhibit Cancer Lung Metastases through Disruption of the Myeloid Environment in Pre-metastatic Niches

Unmet NeedCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Recurrence post-surgery can be driven by a number of factors,...

Published: 5/9/2024 | Inventor(s): Malcolm Brock, Zhihao Lu

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules

Locoregional Chemotherapy for Liver Cancers

Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...

Published: 5/9/2024 | Inventor(s): Florin Selaru, Ling Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer

Discovery of Novel Compounds that Enhance Enteric Nervous System Function

Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...

Published: 5/9/2024 | Inventor(s): David Hackam, Peng Lu, Chhinder Sodhi

Keywords(s): Agonists/Promoters, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Alpha particle formulations for treatment of solid tumors

Unmet NeedHepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and a leading cause of cancer related deaths. HCC is clinically silent in its early stages, leading to diagnosis at more advanced stages when only non-surgical, palliative treatment is available. One treatment option for advanced HCC is intra-arterial therapy and...

Published: 5/9/2024 | Inventor(s): Jessie Nedrow, Eleni Liapi

Keywords(s): Biologics, Cancers, Disease Indication, Liver Cancer, Non-novel, Predicted Novelty, Radioisotope Therapy, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

1 2 3 4 5 6